IL2 and cancer: In this phase III randomized trial for 174 primary lung carcinoma patients, autologous LAK cells (1–5 × 109 cells/1 shot) with IL-2 were given combined with or after standard cancer therapy every 2–3 months for 2 years, and the 5- and 9-year survival rates of the immunotherapy group were 54.5% and 52% respectively, compared to 33.4% and 24.2% in the control group (p < 0.001) [53].